Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Total study duration up to 74 weeks: screening up to 4 weeks, AID assessment phase of 12 weeks, extension phase of 52 weeks and post-treatment follow-up of 6 weeks.
For participants not entering the extension phase, total study duration up to 22 weeks (screening, AID assessment phase and follow-up).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of RA, ≥3 months disease duration;
Participant willing and able to self-inject;
Continuous treatment with 1 or a combination of non-biologic disease modifying antirheumatic drugs (DMARDs) (except leflunomide in combination with methotrexate);
Moderate-to-severely active RA.
You may not be if
Participants \<18 years;
Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonists;
Treatment with tumor necrosis factor (TNF) antagonists;
Treatment with RA-directed biologic agents other than with a TNF-α antagonist mechanism as follows: Anakinra, Abatacept, Rituximab or other cell-depleting agent;
Prior treatment with a Janus kinase inhibitor.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Clareo Health | To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
